Anthony Zook
Executive Chairman
Mr. Zook has served as our Executive Chairman and a member of the Board since December 2020. Mr. Zook was executive vice president of global commercial operations of AstraZeneca Plc from 2010 until 2012.
Patrick Gallagher, CFA
Chief Executive Officer
He has 20 years of healthcare experience on Wall Street including alternative investments, research and marketing in both the public and private markets.
Matthew Duffy
President, Treasurer, Director
Matt has served as Chief Executive Officer & board member of Algorithm Sciences, Inc. since September 2010, and has more than thirty years’ experience in the healthcare arena, as both a healthcare and Wall Street executive.
Zachary Shriver, PhD
CSO, Visterra Inc.
Dr. Zachary Shriver has joined the team to provide expertise in protein design, development and manufacturing; globally recognized expert in protein manufacturing.
Paul Korner, MD, MBA
Director
Paul Korner is physician executive with over 21 years of pharmaceutical/biotech industry experience, serving in senior R & D leadership position for Ferring Pharmaceuticals, Ardelyx Inc., Sarepta Therapeutics and Axovant Gene Therapies.
James P. Ahern
Director
James Ahern is a director of Voltron Therapeutics. With more than 18 years of experience in investment banking, capital formation, venture capital, and equity capital markets, he brings the Voltron team significant added value.
Matthew D. Eitner
Director
Matthew Eitner is a director of Voltron Therapeutics. He is also CEO of Laidlaw & Company UK. At Laidlaw, he greatly expanded the company’s healthcare equity and hired renowned figures to direct its expanded teams.
Scientific Team
Dr. Mark C Poznansky
Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting and to help gather additional academic and clinical KOLs to serve on the SAB.
Jeffrey Gelfand, MD
Dr. Jeffrey A. Gelfand is an infectious disease specialist in Boston, Massachusetts. He received his medical degree from Tufts University School of Medicine and has been in practice for more than 20 years. Dr. Gelfand’s specializes in infectious disease. He is also a Clinical Professor of Medicine, where he has developed a novel approach for targeting (tumor) antigens whose sequence may not be known or structure even identified.